Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Biogen-BioThera Biosimilar of Roche Drug Approved in US for Arthritis

publication date: Oct 2, 2023

Biogen, a Cambridge, MA biopharma, announced US approval for Tofidence (tocilizumab-bavi), a biosimilar to Roche’s Actemra® (tocilizumab), which Biogen in-licensed from Guangzhou's Bio-Thera. The candidate, which is the first tocilizumab biosimilar approved in the US, is indicated for various arthritis indications, especially for young people. In 2021, Bio-Thera sold ex-China rights for tocilizumab-bavi to Biogen for a $30 million payment due once the candidate posted results from a US Phase III trial showing non-inferiority to Roche’s target drug. Biogen has exclusive regulatory, manufacturing and commercial rights to Tofidence outside of China. More details....

Stock Symbols: (NSDQ: BIIB) (SHA: 688177)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital